These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

577 related items for PubMed ID: 21271613

  • 21. A Meta-Analysis and Indirect Comparison of Endothelin A Receptor Antagonist for Castration-Resistant Prostate Cancer.
    Qi P, Chen M, Zhang LX, Song RX, He ZH, Wang ZP.
    PLoS One; 2015; 10(7):e0133803. PubMed ID: 26192308
    [Abstract] [Full Text] [Related]

  • 22. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer.
    Heck MM, Thalgott M, Retz M, Wolf P, Maurer T, Nawroth R, Hatzichristodoulou G, Gschwend JE, Kübler H.
    BJU Int; 2012 Dec; 110(11 Pt B):E635-40. PubMed ID: 22889368
    [Abstract] [Full Text] [Related]

  • 23. Docetaxel plus prednisolone for the treatment of metastatic hormone-refractory prostate cancer: a multicenter Phase II trial in Japan.
    Naito S, Tsukamoto T, Koga H, Harabayashi T, Sumiyoshi Y, Hoshi S, Akaza H.
    Jpn J Clin Oncol; 2008 May; 38(5):365-72. PubMed ID: 18417502
    [Abstract] [Full Text] [Related]

  • 24. Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients.
    Buonerba C, Federico P, D'Aniello C, Rescigno P, Cavaliere C, Puglia L, Ferro M, Altieri V, Perdonà S, De Placido S, Di Lorenzo G.
    Cancer Chemother Pharmacol; 2011 Jun; 67(6):1455-61. PubMed ID: 21365219
    [Abstract] [Full Text] [Related]

  • 25. Salvage therapy with oral metronomic cyclophosphamide and methotrexate for castration-refractory metastatic adenocarcinoma of the prostate resistant to docetaxel.
    Gebbia V, Serretta V, Borsellino N, Valerio MR, GSTU Foundation.
    Urology; 2011 Nov; 78(5):1125-30. PubMed ID: 22054386
    [Abstract] [Full Text] [Related]

  • 26. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
    Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, Linassier C, Scotté F, Banu A, Coscas Y, Guinet F, Poupon MF, Andrieu JM.
    J Clin Oncol; 2005 May 20; 23(15):3343-51. PubMed ID: 15738542
    [Abstract] [Full Text] [Related]

  • 27. A phase 1 study of a chimeric monoclonal antibody against interleukin-6, siltuximab, combined with docetaxel in patients with metastatic castration-resistant prostate cancer.
    Hudes G, Tagawa ST, Whang YE, Qi M, Qin X, Puchalski TA, Reddy M, Cornfeld M, Eisenberger M.
    Invest New Drugs; 2013 Jun 20; 31(3):669-76. PubMed ID: 22828917
    [Abstract] [Full Text] [Related]

  • 28. A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer.
    Krainer M, Tomek S, Elandt K, Horak P, Albrecht W, Eisenmenger M, Höltl W, Schramek P, Stackl W, Zielinski C, Reibenwein J.
    J Urol; 2007 Jun 20; 177(6):2141-5; discussion 2145. PubMed ID: 17509302
    [Abstract] [Full Text] [Related]

  • 29. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer.
    Scher HI, Jia X, Chi K, de Wit R, Berry WR, Albers P, Henick B, Waterhouse D, Ruether DJ, Rosen PJ, Meluch AA, Nordquist LT, Venner PM, Heidenreich A, Chu L, Heller G.
    J Clin Oncol; 2011 Jun 01; 29(16):2191-8. PubMed ID: 21483004
    [Abstract] [Full Text] [Related]

  • 30. Docetaxel reintroduction in patients with metastatic castration-resistant docetaxel-sensitive prostate cancer: a retrospective multicentre study.
    Eymard JC, Oudard S, Gravis G, Ferrero JM, Theodore C, Joly F, Priou F, Krakowski I, Zannetti A, Thill L, Beuzeboc P.
    BJU Int; 2010 Oct 01; 106(7):974-8. PubMed ID: 20230389
    [Abstract] [Full Text] [Related]

  • 31. Pharmacokinetic and tolerability profile of once-daily zibotentan (ZD4054) in Japanese and Caucasian patients with hormone-resistant prostate cancer.
    Ranson M, Wilson RH, O'Sullivan JM, Maruoka M, Yamaguchi A, Cowan RA, Logue JP, Tomkinson H, Tominaga N, Swaisland H, Oliver S, Usami M.
    Int J Clin Pharmacol Ther; 2010 Nov 01; 48(11):708-17. PubMed ID: 20979929
    [Abstract] [Full Text] [Related]

  • 32. Phase II study of docetaxel re-treatment in docetaxel-pretreated castration-resistant prostate cancer.
    Di Lorenzo G, Buonerba C, Faiella A, Rescigno P, Rizzo M, Autorino R, Perdonà S, Riccardi N, Scagliorini S, Scognamiglio F, Masala D, Ferro M, Palmieri G, Aieta M, Marinelli A, Altieri V, De Placido S, Cartenì G.
    BJU Int; 2011 Jan 01; 107(2):234-9. PubMed ID: 20590545
    [Abstract] [Full Text] [Related]

  • 33. Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer.
    Sonpavde G, Matveev V, Burke JM, Caton JR, Fleming MT, Hutson TE, Galsky MD, Berry WR, Karlov P, Holmlund JT, Wood BA, Brookes M, Leopold L.
    Ann Oncol; 2012 Jul 01; 23(7):1803-8. PubMed ID: 22112969
    [Abstract] [Full Text] [Related]

  • 34. Docetaxel in the treatment of metastatic castration-resistant prostate cancer (mCRPC): an observational study in a single institution.
    Schallier D, Decoster L, Braeckman J, Fontaine C, Degrève J.
    Anticancer Res; 2012 Feb 01; 32(2):633-41. PubMed ID: 22287756
    [Abstract] [Full Text] [Related]

  • 35. Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer.
    Ferrero JM, Chamorey E, Oudard S, Dides S, Lesbats G, Cavaglione G, Nouyrigat P, Foa C, Kaphan R.
    Cancer; 2006 Aug 15; 107(4):738-45. PubMed ID: 16826591
    [Abstract] [Full Text] [Related]

  • 36. A phase II study of the antisense oligonucleotide GTI-2040 plus docetaxel and prednisone as first-line treatment in castration-resistant prostate cancer.
    Sridhar SS, Canil CM, Chi KN, Hotte SJ, Ernst S, Wang L, Chen EX, Juhasz A, Yen Y, Murray P, Zwiebel JA, Moore MJ.
    Cancer Chemother Pharmacol; 2011 Apr 15; 67(4):927-33. PubMed ID: 20602233
    [Abstract] [Full Text] [Related]

  • 37. No additional benefit of adding ifosfamide to docetaxel in castration-resistant metastatic prostate cancer.
    Hervonen P, Tulijoki T, Kellokumpu-Lehtinen P.
    Anticancer Res; 2012 Aug 15; 32(8):3305-9. PubMed ID: 22843906
    [Abstract] [Full Text] [Related]

  • 38. Randomized, placebo-controlled, double-blind, phase II study of axitinib plus docetaxel versus docetaxel plus placebo in patients with metastatic breast cancer.
    Rugo HS, Stopeck AT, Joy AA, Chan S, Verma S, Lluch A, Liau KF, Kim S, Bycott P, Rosbrook B, Bair AH, Soulieres D.
    J Clin Oncol; 2011 Jun 20; 29(18):2459-65. PubMed ID: 21555686
    [Abstract] [Full Text] [Related]

  • 39. Leukopenia as a risk factor for osteonecrosis of the jaw in metastatic prostate cancer treated using zoledronic acid and docetaxel.
    Miyazaki H, Nishimatsu H, Kume H, Suzuki M, Fujimura T, Fukuhara H, Enomoto Y, Ishikawa A, Igawa Y, Hirano Y, Homma Y.
    BJU Int; 2012 Dec 20; 110(11 Pt B):E520-5. PubMed ID: 22578070
    [Abstract] [Full Text] [Related]

  • 40. Docetaxel, vinorelbine, and zoledronic acid as first-line treatment in patients with hormone refractory prostate cancer: a phase II study.
    Di Lorenzo G, Autorino R, Perdonà S, De Laurentiis M, D'Armiento M, Cancello G, Mirone V, Imbimbo C, Longo N, Altieri V, Tortora G, Figg WD, De Placido S.
    Eur Urol; 2007 Oct 20; 52(4):1020-7. PubMed ID: 17360103
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 29.